Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Public ClinicalTrials.gov record NCT00353496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Study identification
- NCT ID
- NCT00353496
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Ipsen
- Industry
- Enrollment
- 264 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- lanreotide (Autogel formulation) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Mar 31, 2013
- Completion
- Mar 31, 2013
- Last update posted
- Mar 4, 2025
2006 – 2013
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Outpatient Cancer Center | Los Angeles | California | 90048 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| The John Hopkins Hospital | Baltimore | Maryland | 21287-4606 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| University of Wisconsin School of Medicine and Public Health | Madison | Wisconsin | 53792-5666 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00353496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00353496 live on ClinicalTrials.gov.